Skin is the body’s main protective barrier against injury. Significant wounds caused by burns, physical trauma, surgeries, and other underlying pathologies can lead to impaired tissue regeneration and loss of barrier function. Scaffolds have been used as a therapeutic mechanism for tissue repair and regeneration. Current scaffolds, however, have the limitations of inadequate biocompatibility and biodegradability, mechanical and structural mismatch with the native tissue, and susceptibility to infection.
The current invention addresses the lack of antimicrobial activity and infection control in natural and synthetic tissue replacements by creating a novel cell-derived extracellular matrix (ECM) scaffold with antimicrobial properties. The tailored scaffold has tremendous potential for improving wound healing and infection control, stimulating tissue repair and regeneration, and restoring structure and/or function of a variety of injured tissues.
- The scaffold provides the structural and mechanical properties of native dermis and actively prevents wound infection.
- The cells can be genetically modified to express additional factors, including growth factors, ECM molecules and ECM-associated molecules that promote enhanced angiogenesis, quicker wound closure, functional tissue regeneration, tunable mechanical properties and infection treatment and prevention.
- A fusion protein with these unique binding collagen domains and antimicrobial activities is currently not available in the market.
- Can be applied to any tissue, for example, dermal, periodontal, cardiovascular, orthopedic, craniofacial, musculoskeletal, endocrine, or gastrointestinal. Improved wound healing and tissue regeneration with reduced infection results in lower medical costs and less patient discomfort.